We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
XyloCor Therapeutics raised $17 million in its series A round to advance a gene therapy pipeline for cardiovascular disease. Its lead asset is a treatment for angina that is poised to enter the clinic in 2019....